Heirloom Wealth Management Invests $219,000 in Thermo Fisher Scientific Inc. (NYSE:TMO)

Heirloom Wealth Management purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 1st quarter, Holdings Channel reports. The institutional investor purchased 377 shares of the medical research company’s stock, valued at approximately $219,000.

Other large investors have also recently made changes to their positions in the company. WCM Investment Management LLC raised its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock valued at $527,524,000 after purchasing an additional 2,928 shares during the period. Summa Corp. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $418,000. Phoenix Holdings Ltd. raised its stake in Thermo Fisher Scientific by 21.4% during the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock valued at $4,750,000 after purchasing an additional 1,654 shares during the period. S. R. Schill & Associates boosted its stake in Thermo Fisher Scientific by 106.3% in the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock worth $816,000 after purchasing an additional 792 shares during the period. Finally, Check Capital Management Inc. CA bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $219,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $564.72, for a total value of $5,647,200.00. Following the completion of the transaction, the chief executive officer now directly owns 128,485 shares of the company’s stock, valued at approximately $72,558,049.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction that occurred on Friday, April 26th. The shares were sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the transaction, the senior vice president now directly owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $564.72, for a total transaction of $5,647,200.00. Following the completion of the sale, the chief executive officer now owns 128,485 shares in the company, valued at approximately $72,558,049.20. The disclosure for this sale can be found here. Insiders have sold a total of 32,000 shares of company stock worth $18,486,980 in the last ninety days. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Stock Down 1.0 %

Shares of NYSE TMO traded down $5.77 during midday trading on Thursday, reaching $585.03. 1,167,331 shares of the company’s stock traded hands, compared to its average volume of 1,507,199. The company has a market cap of $223.32 billion, a price-to-earnings ratio of 37.53, a P/E/G ratio of 2.75 and a beta of 0.80. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The stock’s 50 day simple moving average is $576.44 and its 200-day simple moving average is $545.98.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, analysts predict that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Friday, June 14th will be issued a dividend of $0.39 per share. The ex-dividend date is Friday, June 14th. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.01%.

Wall Street Analyst Weigh In

TMO has been the topic of several research analyst reports. The Goldman Sachs Group boosted their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. HSBC increased their target price on Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research report on Tuesday, April 30th. Barclays lifted their price objective on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 25th. Citigroup initiated coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. Finally, JPMorgan Chase & Co. boosted their target price on Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $607.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.